Noxopharm Limited (ASX:NOX)

Australia · Delayed Price · Currency is AUD

0.0490

0.00 (0.00%)

Oct 26, 2026, 12:43 PM AEDT

Market Cap	15.05M -44.6%
Revenue (ttm)	1.43M -49.4%
Net Income	-4.46M
EPS	-0.01
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,540
Open	0.0490
Previous Close	0.0490
Day's Range	0.0490 - 0.0490
52-Week Range	0.0490 - 0.1100
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Noxopharm

Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CR... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol NOX

Full Company Profile

Financial Performance

In fiscal year 2026, Noxopharm's revenue was 1.43 million, a decrease of -49.40% compared to the previous year's 2.82 million. Losses were -4.46 million, -8.77% less than in 2025.

Financial Statements